China Shineway Pharmaceutical Group Stock | 2877.HK | KYG2110P1000 | A0DNLW

Date	China Shineway Pharmaceutical Group Price
9/13/2024	7.25 undefined
9/12/2024	7.40 undefined
9/11/2024	7.29 undefined
9/10/2024	7.36 undefined
9/9/2024	7.55 undefined
9/5/2024	7.72 undefined
9/4/2024	7.66 undefined
9/3/2024	7.76 undefined
9/2/2024	8.01 undefined
8/30/2024	7.96 undefined
8/29/2024	7.85 undefined
8/28/2024	7.34 undefined
8/27/2024	7.50 undefined
8/26/2024	7.44 undefined
8/23/2024	7.40 undefined
8/22/2024	7.54 undefined
8/21/2024	7.62 undefined
8/20/2024	7.56 undefined
8/19/2024	7.60 undefined

Date	China Shineway Pharmaceutical Group Revenue	China Shineway Pharmaceutical Group EBIT	China Shineway Pharmaceutical Group Net Income
2026e	6.85 B undefined	1.77 B undefined	1.43 B undefined
2025e	5.96 B undefined	1.53 B undefined	1.25 B undefined
2024e	5.19 B undefined	1.33 B undefined	1.1 B undefined
2023	4.52 B undefined	1.13 B undefined	969.51 M undefined
2022	3.95 B undefined	826.94 M undefined	722.77 M undefined
2021	3.22 B undefined	636.59 M undefined	556.67 M undefined
2020	2.66 B undefined	515.05 M undefined	295.03 M undefined
2019	2.71 B undefined	562.48 M undefined	503.15 M undefined
2018	2.57 B undefined	533.07 M undefined	505.88 M undefined
2017	1.92 B undefined	487.25 M undefined	451.55 M undefined
2016	1.99 B undefined	588.29 M undefined	589.2 M undefined
2015	2.05 B undefined	697.97 M undefined	657.91 M undefined
2014	2.23 B undefined	755.68 M undefined	704.78 M undefined
2013	2.19 B undefined	775.5 M undefined	683.6 M undefined
2012	2.13 B undefined	724.1 M undefined	647.7 M undefined
2011	1.98 B undefined	883.8 M undefined	755.6 M undefined
2010	2.04 B undefined	943.8 M undefined	821.8 M undefined
2009	1.63 B undefined	712.5 M undefined	767.3 M undefined
2008	1.28 B undefined	575.3 M undefined	398.2 M undefined
2007	1.01 B undefined	425.6 M undefined	490.6 M undefined
2006	841.5 M undefined	342.2 M undefined	333 M undefined
2005	831.4 M undefined	342.5 M undefined	331.5 M undefined
2004	703.6 M undefined	280.8 M undefined	260.8 M undefined

	Revenue	EBIT	Net Income
2004	703.6 M CNY	280.8 M CNY	260.8 M CNY
2005	831.4 M CNY	342.5 M CNY	331.5 M CNY
2006	841.5 M CNY	342.2 M CNY	333 M CNY
2007	1.01 B CNY	425.6 M CNY	490.6 M CNY
2008	1.28 B CNY	575.3 M CNY	398.2 M CNY
2009	1.63 B CNY	712.5 M CNY	767.3 M CNY
2010	2.04 B CNY	943.8 M CNY	821.8 M CNY
2011	1.98 B CNY	883.8 M CNY	755.6 M CNY
2012	2.13 B CNY	724.1 M CNY	647.7 M CNY
2013	2.19 B CNY	775.5 M CNY	683.6 M CNY
2014	2.23 B CNY	755.68 M CNY	704.78 M CNY
2015	2.05 B CNY	697.97 M CNY	657.91 M CNY
2016	1.99 B CNY	588.29 M CNY	589.2 M CNY
2017	1.92 B CNY	487.25 M CNY	451.55 M CNY
2018	2.57 B CNY	533.07 M CNY	505.88 M CNY
2019	2.71 B CNY	562.48 M CNY	503.15 M CNY
2020	2.66 B CNY	515.05 M CNY	295.03 M CNY
2021	3.22 B CNY	636.59 M CNY	556.67 M CNY
2022	3.95 B CNY	826.94 M CNY	722.77 M CNY
2023	4.52 B CNY	1.13 B CNY	969.51 M CNY
2024e	5.19 B CNY	1.33 B CNY	1.1 B CNY
2025e	5.96 B CNY	1.53 B CNY	1.25 B CNY
2026e	6.85 B CNY	1.77 B CNY	1.43 B CNY

China Shineway Pharmaceutical Group Gross margin	China Shineway Pharmaceutical Group Profit margin	China Shineway Pharmaceutical Group EBIT margin	China Shineway Pharmaceutical Group Profit margin
2026e	75.15 %	25.77 %	20.91 %
2025e	75.15 %	25.6 %	20.92 %
2024e	75.15 %	25.68 %	21.18 %
2023	75.15 %	25.09 %	21.47 %
2022	74.38 %	20.93 %	18.3 %
2021	74.77 %	19.75 %	17.27 %
2020	74.85 %	19.39 %	11.11 %
2019	73.23 %	20.79 %	18.59 %
2018	72.99 %	20.74 %	19.68 %
2017	66.01 %	25.38 %	23.52 %
2016	64.54 %	29.51 %	29.56 %
2015	66.23 %	33.97 %	32.02 %
2014	66.3 %	33.9 %	31.62 %
2013	67.41 %	35.46 %	31.26 %
2012	65.28 %	33.96 %	30.38 %
2011	65.61 %	44.54 %	38.08 %
2010	70.4 %	46.3 %	40.32 %
2009	72.13 %	43.63 %	46.98 %
2008	71.7 %	45.11 %	31.23 %
2007	72.86 %	42.02 %	48.44 %
2006	70.39 %	40.67 %	39.57 %
2005	66.95 %	41.2 %	39.87 %
2004	64.18 %	39.91 %	37.07 %

	Gross margin	EBIT margin	Profit margin
2004	64.18 %	39.91 %	37.07 %
2005	66.95 %	41.2 %	39.87 %
2006	70.39 %	40.67 %	39.57 %
2007	72.86 %	42.02 %	48.44 %
2008	71.7 %	45.11 %	31.23 %
2009	72.13 %	43.63 %	46.98 %
2010	70.4 %	46.3 %	40.32 %
2011	65.61 %	44.54 %	38.08 %
2012	65.28 %	33.96 %	30.38 %
2013	67.41 %	35.46 %	31.26 %
2014	66.3 %	33.9 %	31.62 %
2015	66.23 %	33.97 %	32.02 %
2016	64.54 %	29.51 %	29.56 %
2017	66.01 %	25.38 %	23.52 %
2018	72.99 %	20.74 %	19.68 %
2019	73.23 %	20.79 %	18.59 %
2020	74.85 %	19.39 %	11.11 %
2021	74.77 %	19.75 %	17.27 %
2022	74.38 %	20.93 %	18.3 %
2023	75.15 %	25.09 %	21.47 %
2024e	75.15 %	25.68 %	21.18 %
2025e	75.15 %	25.6 %	20.92 %
2026e	75.15 %	25.77 %	20.91 %

Date	China Shineway Pharmaceutical Group Sales per Share	China Shineway Pharmaceutical Group EBIT per share	China Shineway Pharmaceutical Group Earnings per Share
2026e	9.07 undefined	0 undefined	1.9 undefined
2025e	7.89 undefined	0 undefined	1.65 undefined
2024e	6.87 undefined	0 undefined	1.45 undefined
2023	5.98 undefined	1.5 undefined	1.28 undefined
2022	5.23 undefined	1.09 undefined	0.96 undefined
2021	4.27 undefined	0.84 undefined	0.74 undefined
2020	3.51 undefined	0.68 undefined	0.39 undefined
2019	3.47 undefined	0.72 undefined	0.64 undefined
2018	3.14 undefined	0.65 undefined	0.62 undefined
2017	2.32 undefined	0.59 undefined	0.55 undefined
2016	2.41 undefined	0.71 undefined	0.71 undefined
2015	2.48 undefined	0.84 undefined	0.8 undefined
2014	2.7 undefined	0.91 undefined	0.85 undefined
2013	2.64 undefined	0.94 undefined	0.83 undefined
2012	2.58 undefined	0.88 undefined	0.78 undefined
2011	2.4 undefined	1.07 undefined	0.91 undefined
2010	2.46 undefined	1.14 undefined	0.99 undefined
2009	1.97 undefined	0.86 undefined	0.93 undefined
2008	1.54 undefined	0.7 undefined	0.48 undefined
2007	1.22 undefined	0.51 undefined	0.59 undefined
2006	1.02 undefined	0.41 undefined	0.4 undefined
2005	1 undefined	0.41 undefined	0.4 undefined
2004	1.14 undefined	0.45 undefined	0.42 undefined

	Sales per Share	EBIT per share	Earnings per Share
2004	1.14 CNY	0.45 CNY	0.42 CNY
2005	1 CNY	0.41 CNY	0.4 CNY
2006	1.02 CNY	0.41 CNY	0.4 CNY
2007	1.22 CNY	0.51 CNY	0.59 CNY
2008	1.54 CNY	0.7 CNY	0.48 CNY
2009	1.97 CNY	0.86 CNY	0.93 CNY
2010	2.46 CNY	1.14 CNY	0.99 CNY
2011	2.4 CNY	1.07 CNY	0.91 CNY
2012	2.58 CNY	0.88 CNY	0.78 CNY
2013	2.64 CNY	0.94 CNY	0.83 CNY
2014	2.7 CNY	0.91 CNY	0.85 CNY
2015	2.48 CNY	0.84 CNY	0.8 CNY
2016	2.41 CNY	0.71 CNY	0.71 CNY
2017	2.32 CNY	0.59 CNY	0.55 CNY
2018	3.14 CNY	0.65 CNY	0.62 CNY
2019	3.47 CNY	0.72 CNY	0.64 CNY
2020	3.51 CNY	0.68 CNY	0.39 CNY
2021	4.27 CNY	0.84 CNY	0.74 CNY
2022	5.23 CNY	1.09 CNY	0.96 CNY
2023	5.98 CNY	1.5 CNY	1.28 CNY
2024e	6.87 CNY	0 CNY	1.45 CNY
2025e	7.89 CNY	0 CNY	1.65 CNY
2026e	9.07 CNY	0 CNY	1.9 CNY

	Number of stocks
2004	617.2 M Aktien
2005	828.6 M Aktien
2006	827 M Aktien
2007	827 M Aktien
2008	827 M Aktien
2009	827 M Aktien
2010	827 M Aktien
2011	827 M Aktien
2012	827 M Aktien
2013	827 M Aktien
2014	827 M Aktien
2015	827 M Aktien
2016	827 M Aktien
2017	827 M Aktien
2018	817.86 M Aktien
2019	780.95 M Aktien
2020	756.75 M Aktien
2021	755.14 M Aktien
2022	755.4 M Aktien
2023	755.4 M Aktien
2024e	755.4 M Aktien
2025e	755.4 M Aktien
2026e	755.4 M Aktien

Date	China Shineway Pharmaceutical Group Dividend
2026e	0.49 undefined
2025e	0.49 undefined
2024e	0.49 undefined
2023	0.47 undefined
2022	0.38 undefined
2021	0.72 undefined
2020	0.22 undefined
2019	0.26 undefined
2018	0.24 undefined
2017	0.23 undefined
2016	0.27 undefined
2015	0.23 undefined
2014	0.21 undefined
2013	0.23 undefined
2012	0.25 undefined
2011	0.28 undefined
2010	0.23 undefined
2009	0.22 undefined
2008	0.12 undefined
2007	0.13 undefined
2006	0.12 undefined
2005	0.1 undefined

	Dividend	Dividend (Estimate)
2004	0 CNY	0 CNY
2005	0.1 CNY	0 CNY
2006	0.12 CNY	0 CNY
2007	0.13 CNY	0 CNY
2008	0.12 CNY	0 CNY
2009	0.22 CNY	0 CNY
2010	0.23 CNY	0 CNY
2011	0.28 CNY	0 CNY
2012	0.25 CNY	0 CNY
2013	0.23 CNY	0 CNY
2014	0.21 CNY	0 CNY
2015	0.23 CNY	0 CNY
2016	0.27 CNY	0 CNY
2017	0.23 CNY	0 CNY
2018	0.24 CNY	0 CNY
2019	0.26 CNY	0 CNY
2020	0.22 CNY	0 CNY
2021	0.72 CNY	0 CNY
2022	0.38 CNY	0 CNY
2023	0.47 CNY	0 CNY
2024e	0 CNY	0.49 CNY
2025e	0 CNY	0.49 CNY
2026e	0 CNY	0.49 CNY

Date	China Shineway Pharmaceutical Group Payout ratio
2026e	63.2 %
2025e	57.4 %
2024e	67.4 %
2023	64.78 %
2022	40.03 %
2021	97.4 %
2020	56.92 %
2019	40.46 %
2018	38.53 %
2017	42.38 %
2016	38.09 %
2015	29.34 %
2014	24.64 %
2013	27.71 %
2012	32.05 %
2011	30.77 %
2010	23.23 %
2009	23.66 %
2008	25 %
2007	22.03 %
2006	30 %
2005	25 %
2004	64.78 %

	Payout ratio
2004	64.78 %
2005	25 %
2006	30 %
2007	22.03 %
2008	25 %
2009	23.66 %
2010	23.23 %
2011	30.77 %
2012	32.05 %
2013	27.71 %
2014	24.64 %
2015	29.34 %
2016	38.09 %
2017	42.38 %
2018	38.53 %
2019	40.46 %
2020	56.92 %
2021	97.4 %
2022	40.03 %
2023	64.78 %
2024e	67.4 %
2025e	57.4 %
2026e	63.2 %

Date	EPS Estimate	EPS Actual	Quarterly report
6/30/2017	0.31	0.22 (-28.1 %)	2017 Q2
6/30/2015	0.5	0.47 (-5.96 %)	2015 Q2
12/31/2014	0.38	0.36 (-4.61 %)	2014 Q4
6/30/2014	0.47	0.49 (5.35 %)	2014 Q2
6/30/2013	0.44	0.47 (7.16 %)	2013 Q2
12/31/2012	0.44	0.35 (-20.2 %)	2012 Q4
6/30/2012	0.5	0.43 (-13.97 %)	2012 Q2
6/30/2011	0.47	0.53 (12.96 %)	2011 Q2
12/31/2010	0.41	0.48 (17.07 %)	2010 Q4

%	Name	Stocks	Change	Date
72.38589 %	Forway Investment Ltd.	546,802,990	0	12/31/2022
1.19938 %	The Vanguard Group, Inc.	9,060,082	0	3/31/2024
0.82118 %	Dimensional Fund Advisors, L.P.	6,203,200	48,000	1/31/2024
0.76781 %	BlackRock Institutional Trust Company, N.A.	5,800,000	0	3/31/2024
0.47697 %	Fullgoal Fund Management Co., Ltd.	3,603,000	1,046,000	12/31/2023
0.44453 %	California State Teachers Retirement System	3,358,000	766,300	6/30/2023
0.33454 %	Norges Bank Investment Management (NBIM)	2,527,084	-410,607	12/31/2023
0.21618 %	Nuveen LLC	1,633,000	0	3/31/2024
0.18516 %	BlackRock Advisors (UK) Limited	1,398,728	1,000	3/31/2024
0.16164 %	Allianz Global Investors GmbH	1,221,000	0	2/29/2024
0.14742 %	Florida State Board of Administration	1,113,600	-818,543	9/30/2022
0.13503 %	Li (Huimin)	1,020,000	0	12/31/2022
0.10870 %	State Street Global Advisors (US)	821,138	-25,000	3/31/2024
0.07996 %	Union Investment Luxembourg S.A.	604,000	0	12/31/2023
0.07149 %	Xin (Yunxia)	540,000	0	12/31/2022
0.05639 %	Dimensional Fund Advisors, Ltd.	426,000	0	1/31/2024
0.05057 %	AXA Investment Managers UK Ltd.	382,000	0	2/29/2024
0.04819 %	American Century Investment Management, Inc.	364,000	0	3/31/2024
0.03971 %	ÖKOWORLD LUX S.A.	300,000	0	12/31/2023
0.03680 %	BlackRock Financial Management, Inc.	278,000	0	11/30/2023
0.03310 %	1741 Fund Solutions AG	250,000	0	2/29/2024
0.03234 %	Mackenzie Financial Corporation	244,296	-26,076	12/31/2023
0.03045 %	Segall Bryant & Hamill, LLC	230,000	0	2/29/2024
0.02211 %	Jupiter Asset Management Ltd.	167,000	122,000	12/31/2023
0.02122 %	State Street Global Advisors (UK) Ltd.	160,271	0	2/29/2024
0.01779 %	State Street Global Advisors (Japan) Co., Ltd.	134,399	0	2/29/2024
0.01456 %	Parametric Portfolio Associates LLC	110,000	0	1/31/2024
0.01249 %	DFA Australia Ltd.	94,376	23,376	12/31/2023
0.01178 %	Avantis Investors	89,000	0	3/31/2024
0.01112 %	Schroder Investment Management Ltd. (SIM)	84,000	0	3/31/2023
0.00966 %	State Street Global Advisors Ireland Limited	73,000	0	3/31/2024
0.00953 %	Signal Iduna Asset Management GmbH	72,000	0	12/31/2023
0.00543 %	Finlabo SIM S.p. A.	41,000	0	2/29/2024
0.00530 %	Dr. Bost & Compagnon Vermögensberatungs GmbH & Co.KG	40,000	30,000	12/31/2023
0.00516 %	Grantham Mayo Van Otterloo & Co LLC	39,000	-26,000	11/30/2023
0.00477 %	Legal & General Investment Management Ltd.	36,000	36,000	12/31/2023
0.00424 %	Vanguard Global Advisers LLC	32,000	1,000	2/29/2024
0.00270 %	Vanguard Investments Australia Ltd.	20,400	14	2/29/2024
0.00093 %	Connor, Clark & Lunn Investment Management Ltd.	7,000	0	9/30/2023
0.00053 %	Prudential Capital Group	4,000	0	11/30/2022
0.00013 %	GMO UK Limited	1,000	-5,000	9/30/2023
0 %	Chen (Zhong)	0	-280,000	10/31/2022
0 %	Artico Partners AG	0	-24,000	12/31/2023
0 %	Bellevue Asset Management AG	0	-332,200	6/30/2023
0 %	Skagen AS	0	-887,890	8/31/2022
0 %	PGIM Quantitative Solutions LLC	0	-10,000	12/31/2023
0 %	Handelsbanken Kapitalförvaltning AB	0	-1,311,098	11/30/2023
0 %	Schroder Investment Management North America Inc.	0	-590,000	3/31/2023
0 %	Lazard Asset Management, L.L.C.	0	-26,000	1/31/2023
0 %	Macquarie Investment Management Global Ltd.	0	-21,000	5/31/2023

What values and corporate philosophy does China Shineway Pharmaceutical Group represent?

China Shineway Pharmaceutical Group Ltd represents a strong set of values and corporate philosophy. The company is committed to delivering high-quality pharmaceutical products and healthcare solutions. With a focus on innovation, they strive to improve the well-being of individuals and communities. China Shineway Pharmaceutical Group Ltd places great importance on research and development, aiming to develop safe and effective medications. They prioritize ethical business practices, promoting transparency and integrity in their operations. By constantly adapting to the changing healthcare landscape, China Shineway Pharmaceutical Group Ltd aims to provide value to their stakeholders and contribute to the advancement of the pharmaceutical industry.

In which countries and regions is China Shineway Pharmaceutical Group primarily present?

China Shineway Pharmaceutical Group Ltd is primarily present in the People's Republic of China. With its headquarters in Beijing, the company has a strong presence throughout China's major cities and provinces. It operates a widespread network of production facilities, research and development centers, and distribution channels across the country. As a leading pharmaceutical company in China, Shineway also exports its products to various countries and regions around the world. However, its main focus and market presence revolve around serving the domestic market within China.

What significant milestones has the company China Shineway Pharmaceutical Group achieved?

China Shineway Pharmaceutical Group Ltd, a leading pharmaceutical company, has achieved numerous significant milestones in its journey. Over the years, the company has made remarkable progress in the research, development, and commercialization of innovative pharmaceutical products. China Shineway Pharmaceutical has successfully launched several breakthrough drugs, revolutionizing the treatment options for various medical conditions. Moreover, the company has established strategic collaborations with international partners, expanding its global presence and enhancing its market competitiveness. With a strong commitment to quality and innovation, China Shineway Pharmaceutical continues to excel in the pharmaceutical industry, providing effective and reliable healthcare solutions to patients worldwide.

What is the history and background of the company China Shineway Pharmaceutical Group?

China Shineway Pharmaceutical Group Ltd, founded in 1996, is a renowned Chinese pharmaceutical company engaged in the research, development, production, and sale of traditional Chinese medicine (TCM) products. With a rich history spanning over two decades, the company has emerged as a leading player in the field of TCM. It focuses on integrating modern scientific research with traditional medicine, aiming to provide safe and effective healthcare solutions. China Shineway Pharmaceutical Group Ltd has established itself as a trusted name in the pharmaceutical industry, constantly striving for innovation and quality in its products.

Who are the main competitors of China Shineway Pharmaceutical Group in the market?

The main competitors of China Shineway Pharmaceutical Group Ltd in the market include Jiangsu Hengrui Medicine Co., Ltd., Sino Biopharmaceutical Limited, CSPC Pharmaceutical Group Limited, and Shanghai Pharmaceuticals Holding Co., Ltd.

In which industries is China Shineway Pharmaceutical Group primarily active?

China Shineway Pharmaceutical Group Ltd is primarily active in the pharmaceutical industry. As a leading Chinese pharmaceutical company, China Shineway Pharmaceutical Group Ltd focuses on the research, development, production, and sales of a wide range of pharmaceutical products. With its vast portfolio, the company is dedicated to providing innovative and high-quality medicines to improve global healthcare. China Shineway Pharmaceutical Group Ltd's expertise lies in various therapeutic areas, including cardiovascular diseases, oncology, and infectious diseases. Through its commitment to innovation and excellence, the company continues to make significant contributions to the advancement of the pharmaceutical industry.

What is the business model of China Shineway Pharmaceutical Group?

The business model of China Shineway Pharmaceutical Group Ltd revolves around developing, manufacturing, and marketing traditional Chinese medicine products. With a focus on herbal medicine research and production, the company strives to provide high-quality healthcare solutions to consumers. By leveraging its robust supply chain, rigorous quality control measures, and extensive distribution network, China Shineway Pharmaceutical Group Ltd aims to cater to the growing demand for traditional medicine both domestically and internationally. Through its commitment to innovation, the company continuously strives to improve medical treatments and enhance the overall well-being of individuals, making it a leading player in the pharmaceutical industry.

What is the P/E ratio of China Shineway Pharmaceutical Group 2024?

The China Shineway Pharmaceutical Group P/E ratio is 4.99.

What is the P/S ratio of China Shineway Pharmaceutical Group 2024?

The China Shineway Pharmaceutical Group P/S ratio is 1.06.

What is the AlleAktien quality score of China Shineway Pharmaceutical Group?

The AlleAktien quality score for China Shineway Pharmaceutical Group is 8/10.

What is the revenue of China Shineway Pharmaceutical Group 2024?

The expected China Shineway Pharmaceutical Group revenue is 5.19 B CNY.

How high is the profit of China Shineway Pharmaceutical Group 2024?

The expected China Shineway Pharmaceutical Group profit is 1.1 B CNY.

What is the business model of China Shineway Pharmaceutical Group

China Shineway Pharmaceutical is one of the largest and leading companies in the Chinese pharmaceutical industry. It was founded in 1996 and is headquartered in Beijing. Shineway's business model is based on research, development, production, and distribution of innovative medicines, health products, and medical technology. The company operates in three main business segments: Authentic Medicine (AM), Modern Chinese Medicine (MCM), and Health Products (HP). Authentic Medicine is the focus of Shineway's business. They offer traditional Chinese medicines as well as other medicines that result from research and development. The AM unit specializes in developing drugs to improve human health. The company understands that they need to be a trusted player in the market and their efforts to comply with international standards prove this. For example, Shineway develops drugs to treat cancer, cardiovascular diseases, infections, and metabolic disorders. The company has partnerships and cooperation agreements with leading academic institutions and biotechnology companies around the world to drive innovation and introduce them to the market. Modern Chinese Medicine (MCM) is Shineway's second major business segment. It combines traditional Chinese medicine (TCM) and Western medicine. Shineway recognizes the advantages of TCM and offers an optimized treatment through various researches, medical studies, and clinical trials. In doing so, Shineway contributes to the improvement of medical care in China and contributes to the coexistence of modern and traditional medicine. Health Products (HP) is Shineway's third business segment. It focuses on the needs and requirements of consumers. Shineway offers a wide range of products tailored to the needs of consumers. This includes products to strengthen the immune system, dietary supplements, and natural remedies. Shineway has presented alternative solutions to traditional Chinese treatment alternatives and offered products to improve quality of life. Overall, Shineway's business model is focused on promoting advancements in medical research and product development as well as improving the medical industry. It combines innovative and traditional approaches, allowing them to be represented in different industries and offer a wide portfolio. Shineway has helped revolutionize the Chinese pharmaceutical industry and establish itself as a trusted market leader in the industry.

What is the China Shineway Pharmaceutical Group dividend?

China Shineway Pharmaceutical Group pays a dividend of 0.38 CNY distributed over payouts per year.

How often does China Shineway Pharmaceutical Group pay dividends?

The dividend cannot currently be calculated for China Shineway Pharmaceutical Group or the company does not pay out a dividend.

What is the China Shineway Pharmaceutical Group ISIN?

The ISIN of China Shineway Pharmaceutical Group is KYG2110P1000.

What is the China Shineway Pharmaceutical Group WKN?

The WKN of China Shineway Pharmaceutical Group is A0DNLW.

What is the China Shineway Pharmaceutical Group ticker?

The ticker of China Shineway Pharmaceutical Group is 2877.HK.

How much dividend does China Shineway Pharmaceutical Group pay?

Over the past 12 months, China Shineway Pharmaceutical Group paid a dividend of 0.47 CNY . This corresponds to a dividend yield of about 6.49 %. For the coming 12 months, China Shineway Pharmaceutical Group is expected to pay a dividend of 0.49 CNY.

What is the dividend yield of China Shineway Pharmaceutical Group?

The current dividend yield of China Shineway Pharmaceutical Group is 6.49 %.

When does China Shineway Pharmaceutical Group pay dividends?

China Shineway Pharmaceutical Group pays a quarterly dividend. This is distributed in the months of October, May, June, October.

How secure is the dividend of China Shineway Pharmaceutical Group?

China Shineway Pharmaceutical Group paid dividends every year for the past 22 years.

What is the dividend of China Shineway Pharmaceutical Group?

For the upcoming 12 months, dividends amounting to 0.49 CNY are expected. This corresponds to a dividend yield of 6.81 %.

In which sector is China Shineway Pharmaceutical Group located?

China Shineway Pharmaceutical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von China Shineway Pharmaceutical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of China Shineway Pharmaceutical Group from 9/27/2024 amounting to 0.12 CNY, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did China Shineway Pharmaceutical Group pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of China Shineway Pharmaceutical Group in the year 2023?

In the year 2023, China Shineway Pharmaceutical Group distributed 0.383 CNY as dividends.

In which currency does China Shineway Pharmaceutical Group pay out the dividend?

The dividends of China Shineway Pharmaceutical Group are distributed in CNY.

2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

0.33	0.34	0.3	1.15	1.35	1.58	1.68	1.59	2.32	2.35	2.17	2.21	2.29	2.69	2.83	3.22	3.53	3.61	3.95	3.94	4.21	5.05	5.91
60.3	126.8	36.1	7.5	3	3.3	8.9	10.7	5.9	7	13.4	20.4	10.1	12.93	31.05	51.12	71.82	174.03	260.03	311.79	424.46	673.38	758.21
24.2	61	57.3	187	134.5	63.3	244.8	298	75.6	263.7	404.3	501.2	669.9	580.88	428.22	504	460.96	357.78	414.29	448.92	400.73	301.68	502.16
29.3	37.6	46.3	18.2	35.5	38.2	78.4	76.3	136.3	191.9	282.8	204	244.5	285.67	340.86	294.41	280.21	405.5	430.8	443	587.96	657.66	897.71
6.9	2.1	5	11.5	17.6	23.2	34	43.1	148.8	129.8	126	123.5	660.8	382.1	214.15	183.07	214.92	104.15	151.93	372.32	80.25	103.18	87.88
0.45	0.57	0.44	1.37	1.54	1.71	2.04	2.01	2.68	2.94	3	3.06	3.88	3.95	3.84	4.25	4.56	4.65	5.2	5.52	5.7	6.78	8.15
0.13	0.19	0.19	0.18	0.23	0.22	0.28	0.33	0.46	0.78	1.11	1.4	1.6	1.57	1.53	1.47	1.4	1.4	1.49	1.39	1.25	1.22	1.21
0	0	0	0	0	0	0	0	0	0	0	17	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	67.48	0
0	0	0	0	0	0	0	0	0.3	2.2	1.4	0.7	0.5	23.29	388.74	348.35	307.96	287.92	248.27	36.96	66.43	47.35	32.79
0	0	0	0	58.5	58.5	58.5	58.5	58.5	91.7	91.7	91.7	91.7	99.65	159.29	159.29	159.29	159.29	159.29	102.5	165.96	165.96	165.96
1.1	1.6	0.3	20	17.4	14.8	27.2	27.9	69.6	160.1	176.3	173.9	169.7	259.92	235.56	240.16	235.74	227.97	26.8	160.24	20.47	19.22	15.23
0.14	0.19	0.19	0.2	0.31	0.3	0.36	0.41	0.59	1.03	1.38	1.68	1.86	1.96	2.31	2.21	2.1	2.08	1.93	1.69	1.5	1.52	1.42
0.58	0.76	0.63	1.57	1.85	2.01	2.41	2.43	3.27	3.97	4.38	4.74	5.74	5.91	6.15	6.47	6.67	6.73	7.13	7.21	7.2	8.3	9.57

0	0	0	88	87.7	87.7	87.7	87.7	87.7	87.7	87.7	87.7	87.7	87.66	87.66	87.66	87.66	87.66	87.66	87.66	87.66	87.66	87.66
0	0	0	982.4	982.4	982.4	982.4	982.4	982.4	982.4	982.4	767.4	767.4	767.39	767.39	767.39	593.72	422.14	422.14	422.14	422.14	422.14	422.14
0.24	0.3	0.4	0.34	0.58	0.73	1.03	1.07	1.65	2.16	2.58	3.14	3.57	4.04	4.44	4.77	5.14	5.56	5.82	5.87	5.97	6.45	7.1
0	0	0	400	-20,700	-32,700	-33,100	0	0	0	0	0	0	0	0	0	0	-304,256	-548,275	-584,712	-578,649	-578,649	-578,649
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.24	0.3	0.4	1.41	1.63	1.77	2.07	2.14	2.72	3.23	3.65	4	4.43	4.89	5.3	5.63	5.82	5.77	5.78	5.79	5.9	6.38	7.03
63.8	112.3	39.8	33.1	58.1	76.1	89.2	64.1	225.2	202.8	289.8	274.8	219.6	202.49	224.13	219.13	230.76	213.11	189.45	164.38	228.62	308.75	484.79
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	856.76	0
0.08	0.08	0.08	0.1	0.16	0.16	0.25	0.23	0.32	0.46	0.36	0.38	0.46	0.48	0.48	0.45	0.48	0.57	0.59	0.65	0.86	1.35	1.65
0	0	0	0	0	0	0	0	0	0	0	0	500	200	0	0	0	0	398.39	369.32	0	0	300
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.66	7.79	7.59	6.53	0.97
0.15	0.19	0.12	0.13	0.22	0.24	0.34	0.29	0.55	0.67	0.65	0.66	1.18	0.89	0.7	0.67	0.71	0.78	1.18	1.19	1.1	2.52	2.43
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.49	15.03	7.32	0.91	0.36
1.1	2.8	5.5	0	0	0	0	0	0	1.1	1.1	1	28.8	23.64	62.95	56.43	60.95	60.63	47	5.3	25.19	18.84	16.26
177.4	226.3	44.9	1.8	0	0	0	0	0	74.7	74.7	90.3	99.9	104.79	92.57	109.1	73.92	125.11	127.92	204.31	171.59	163.99	88.89
178.5	229.1	50.4	1.8	0	0	0	0	0	75.8	75.8	91.3	128.7	128.43	155.52	165.53	134.87	185.74	176.41	224.63	204.11	183.74	105.51
0.33	0.42	0.17	0.13	0.22	0.24	0.34	0.29	0.55	0.74	0.72	0.75	1.31	1.01	0.86	0.84	0.84	0.97	1.35	1.42	1.3	2.71	2.54
0.57	0.73	0.57	1.55	1.85	2.01	2.41	2.43	3.27	3.97	4.38	4.74	5.74	5.91	6.15	6.47	6.67	6.73	7.13	7.21	7.2	9.09	9.57

2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
109	126	185	280	342	387	575	476	884	991	949	799	859	863	797	695	587	669	642	395	720	917
12	14	22	22	25	29	32	36	45	53	65	78	98	144	162	191	194	197	204	208	182	185
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
29	3	-37	-72	101	45	-230	-200	305	-416	-456	-161	-364	-153	-110	-55	-175	-200	-394	-81	-101	133
0	0	0	0	-12	-44	24	93	-177	-48	-73	-80	-73	-81	-104	-96	-116	-133	-85	116	-97	-126
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	16	1	0
24	26	25	13	6	41	61	103	107	136	225	154	156	166	172	101	143	140	157	119	144	156
0.15	0.14	0.17	0.23	0.46	0.42	0.4	0.41	1.06	0.58	0.49	0.64	0.52	0.77	0.74	0.73	0.49	0.53	0.37	0.64	0.7	1.11
-62	-67	-25	-22	-73	-23	-92	-84	-221	-368	-396	-368	-261	-168	-127	-106	-91	-139	-91	-66	-93	-129
-62	-67	-25	-21	-136	10	-53	-35	-268	-236	-328	-290	-675	228	-129	-79	84	112	69	-305	395	-45
0	0	0	0	-62	34	39	48	-47	132	68	78	-413	396	-1	27	176	252	160	-239	488	84
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	500	0	-200	0	0	0	394	-33	-377	-7
0	0	0	1.01	-0.01	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
126	-62	-188	642	-99	-181	-190	-330	-181	-314	-330	-306	235	-605	-473	-264	-264	-565	-100	-329	-828	-250
134	-44	-113	-332	-6	0	0	0	0	0	0	0	0	0	0	0	0	-304	-246	-54	1	0
-7	-17	-74	-32	-82	-181	-190	-330	-181	-314	-330	-306	-264	-272	-272	-264	-264	-261	-249	-241	-453	-241
214	13	-44	851	200	234	96	-92	732	30	-176	39	79	396	138	392	313	79	334	-2	262	820
88	76	143.8	208.5	384.5	394.2	309.4	321.1	836.1	210.5	88.5	266.8	258	604.98	617.35	626.73	398.82	392.79	276.59	572.54	609.52	980.21
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Scope 1 - Direct Emissions	80,760.44
Scope 2 - Indirect emissions from purchased energy	38,727.16
Scope 3 - Indirect emissions within the value chain	20,852.97
Total CO₂ emissions	119,487.6
CO₂ reduction strategy	✅
Coal energy	❌
Nuclear power	❌
Animal experiments	❌
Fur & Leather	—
Pesticides	—
Palm Oil	—
Tobacco	❌
Genetically modified organisms	❌
Climate concept	—
Sustainable forestry	—
Recycling regulations	❌
Environmentally friendly packaging	✅
Hazardous substances	✅
Fuel consumption and efficiency	✅
Water consumption and efficiency	✅

Percentage of female employees	51.95
Percentage of women in management	—
Percentage of Asian employees	—
Share of Asian management	—
Percentage of Hispanic/Latino employees	—
Hispano/Latino Management share	—
Percentage of Black employees	—
Black Management Share	—
Percentage of white employees	—
White Management Share	—
Adult content	❌
Alcohol	❌
Weapons	—
Firearms	❌
Gambling	❌
Military contracts	❌
Human rights concept	✅
Privacy concept	—
Occupational health and safety	✅
Catholic	✅

Environmental reporting	✅
Stakeholder Engagement	✅
Call Back Policies	❌
Antitrust law	❌

2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
0.43	0.48	0.6	0.7	0.83	0.84	1.01	1.28	1.63	2.04	1.98	2.13	2.19	2.23	2.05	1.99	1.92	2.57	2.71	2.66	3.22	3.95	4.52	5.19	5.96	6.85
-	10.93	26.62	16.39	18.21	1.20	20.33	25.99	28.08	24.80	-2.65	7.46	2.58	1.92	-7.85	-2.97	-3.71	33.92	5.29	-1.88	21.39	22.56	14.33	14.86	14.94	14.89
49.77	47.17	47.85	64.15	66.91	70.39	72.92	71.69	72.14	70.41	65.63	65.24	67.40	66.31	66.21	64.53	66.02	73.00	73.21	74.84	74.78	74.38	75.16	-	-	-
0.21	0.23	0.29	0.45	0.56	0.59	0.74	0.91	1.18	1.44	1.3	1.39	1.47	1.48	1.36	1.29	1.27	1.88	1.98	1.99	2.41	2.94	3.39	0	0	0
0.11	0.13	0.19	0.28	0.34	0.34	0.43	0.58	0.71	0.94	0.88	0.72	0.78	0.76	0.7	0.59	0.49	0.53	0.56	0.52	0.64	0.83	1.13	1.33	1.53	1.77
25.35	26.42	30.63	39.83	41.16	40.67	42.00	45.10	43.60	46.27	44.51	33.96	35.44	33.87	33.93	29.50	25.38	20.74	20.77	19.40	19.73	20.91	25.09	25.68	25.60	25.77
0.07	0.08	0.15	0.26	0.33	0.33	0.49	0.4	0.77	0.82	0.76	0.65	0.68	0.7	0.66	0.59	0.45	0.51	0.5	0.3	0.56	0.72	0.97	1.1	1.25	1.43
-	8.45	96.10	72.19	27.31	0.60	47.15	-18.78	92.71	7.04	-8.04	-14.30	5.56	3.07	-6.68	-10.35	-23.43	11.97	-0.40	-41.35	88.47	29.86	34.21	13.31	13.57	14.84
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
600	600	600	617.2	828.6	827	827	827	827	827	827	827	827	827	827	827	827	817.86	780.95	756.75	755.14	755.4	755.4	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

China Shineway Pharmaceutical Group Ticker	China Shineway Pharmaceutical Group FIGI
2877:HK	BBG000BJZ569
C1S:GR	BBG000QZH3Z0
C1S:GF	BBG000QZH4K4
C1S:GS	BBG000QZH5D9
C1S:GM	BBG000QZH5H5
C1S:GB	BBG000QZH5R4
CSWYF:US	BBG000R843Q3
CSWYF:PQ	BBG000R848M6
CSWYF:UV	BBG000R849G1
C1S:TH	BBG000V5B3X8
2877:H1	BBG006Z3JY33
2877:H2	BBG00F135WV8
2877EUR:EO	BBG00F9Q4LH0
2877EUR:XH	BBG00F9Q4LL5
2877EUR:XF	BBG00F9Q4LN3
2877EUR:XE	BBG00F9Q4LQ0
2877EUR:XJ	BBG00F9Q4LR9
2877EUR:XL	BBG00F9Q4LS8
2877EUR:XG	BBG00F9Q4LT7
2877EUR:XO	BBG00F9Q4LV4
2877EUR:XS	BBG00F9Q4LZ0
2877EUR:XA	BBG00F9Q4M06
2877EUR:E1	BBG00F9Q4M15
2877EUR:XT	BBG00F9Q4M24
2877EUR:XW	BBG00F9Q4M33
2877EUR:XU	BBG00F9Q4M42
2877EUR:XV	BBG00F9Q4M51
2877EUR:EU	BBG00F9Q4M79
2877EUR:XX	BBG00JN8KDL1
2877N:L3	BBG00JRFGWT6
2877N:B3	BBG00JRFNDJ1
2877N:PO	BBG00JRFTXY4
2877HKD:X2	BBG00JRGJQG8
2877HKD:XB	BBG00JRGJQH7
2877HKD:XH	BBG00JRGJQK3
2877HKD:XF	BBG00JRGJQM1
2877HKD:XE	BBG00JRGJQP8
2877HKD:XJ	BBG00JRGJQQ7
2877HKD:XL	BBG00JRGJQR6
2877HKD:XG	BBG00JRGJQS5
2877HKD:XO	BBG00JRGJQT4
2877HKD:XS	BBG00JRGJQY8
2877HKD:XA	BBG00JRGJQZ7
2877HKD:E1	BBG00JRGJR03
2877HKD:XT	BBG00JRGJR12
2877HKD:XW	BBG00JRGJR21
2877HKD:XU	BBG00JRGJR30
2877HKD:XV	BBG00JRGJR49
2877HKD:XM	BBG00JRGJR58
2877HKD:XQ	BBG00JRGJR76
2877HKD:XX	BBG00JRGJR85
2877HKD:XZ	BBG00JRGJR94
2877HKD:EU	BBG00JRGJRC0
2877N:L1	BBG00Y7B1QS4
C1S:LA	BBG018H8FLD8
C1S:LU	BBG018J22NY6
C1S:GZ	BBG018Y6ZFZ0

Stock Exchange	China Shineway Pharmaceutical Group Ticker
FRANKFURT	C1S.F
HKSE	2877.HK
MUNICH	C1S.MU
PNK	CSWYF

Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Price

Price

Ticker2877.HK

ISINKYG2110P1000

WKNA0DNLW

China Shineway Pharmaceutical Group stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

China Shineway Pharmaceutical Group Stock Price History

China Shineway Pharmaceutical Group Revenue, EBIT, Net Income KYG2110P1000 · A0DNLW

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

China Shineway Pharmaceutical Group Revenue, EBIT and net profit per share

China Shineway Pharmaceutical Group Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

China Shineway Pharmaceutical Group stock margins KYG2110P1000 · A0DNLW

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

China Shineway Pharmaceutical Group Margin History

China Shineway Pharmaceutical Group Stock Sales Revenue, EBIT, Earnings per Share KYG2110P1000 · A0DNLW

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

China Shineway Pharmaceutical Group Revenue, EBIT and net profit per share

China Shineway Pharmaceutical Group business model

China Shineway Pharmaceutical Group SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

China Shineway Pharmaceutical Group Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

China Shineway Pharmaceutical Group historical P/E ratio, EBIT, and P/S ratio.

China Shineway Pharmaceutical Group shares outstanding KYG2110P1000 · A0DNLW

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

China Shineway Pharmaceutical Group dividend history and estimates KYG2110P1000 · A0DNLW

Dividend

Dividend Overview

Interpretation and Use

Investment Strategy

China Shineway Pharmaceutical Group Dividend History

China Shineway Pharmaceutical Group dividend payout ratio KYG2110P1000 · A0DNLW

Payout ratio

Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Ticker
2877.HK

ISIN
KYG2110P1000

WKN
A0DNLW